Scientific illustration about cannabis, the endocannabinoid system and menstrual pain

Cannabis and Menstrual Pain: What the Real Science Says (2026)

SCIENCEEDU ยท Updated August 2026

Cannabis and Menstrual Pain: What the Real Science Says (2026)

๐Ÿฎธ Between 13% and 27% of women with endometriosis already use cannabis to self-manage their pain, according to several international studies โ€” often without ever mentioning it to their gynecologist. The endocannabinoid system has a documented role in uterine contractility and pain signaling during menstruation. This guide explains the real mechanism, reviews the available studies (including the first trial of a CBD suppository published in 2024), and separates what the evidence supports from what is still marketing promise.

Table of Contents

  1. Why "it's normal for it to hurt" isn't the whole truth
  2. The real mechanism of menstrual pain: prostaglandins
  3. The endocannabinoid system in the uterus
  4. The connection between endocannabinoids and prostaglandins
  5. How the endocannabinoid system changes throughout the cycle
  6. The CBD suppository study: what it actually found
  7. Why the route of administration matters as much as the dose
  8. CBD vs. THC: different mechanisms, not interchangeable
  9. Primary dysmenorrhea vs. endometriosis: not the same thing
  10. PMS and PMDD: does cannabis apply here too?
  11. Topical application on the abdomen: what the evidence says
  12. How many women already use cannabis for this
  13. What consumption methods are actually used
  14. Perceived efficacy vs. quality of the evidence
  15. The real limitations of current research
  16. Interactions and precautions to keep in mind
  17. Legal framework in Spain and Europe
  18. Signs that the pain isn't "normal" and you should see a doctor
  19. Myths vs. reality
  20. Comparison table of administration routes
  21. Frequently asked questions
13-27%
Women with endometriosis who already use cannabis to self-manage their pain, according to several international studies
100mg
CBD dose in the suppository used in the first study published in npj Women's Health (2024)
61-95%
Range of women reporting pain relief with cannabis across different surveys on endometriosis
900+
Women with confirmed endometriosis surveyed in a cross-sectional study in German-speaking countries

1. Why "it's normal for it to hurt" isn't the whole truth ๐Ÿฎธ

Real pain, with a measurable biological basis

Menstrual pain (dysmenorrhea) affects a very large proportion of women of reproductive age, and in a significant subgroup the pain is intense enough to interfere with work, studies, or daily life. Far from being "just something you have to put up with," menstrual pain has identifiable, measurable physiological mechanisms โ€” which opens the door to interventions targeting those specific mechanisms, beyond the classic "take an ibuprofen and wait."

The growing interest in cannabis and its derivatives in this context doesn't come out of nowhere: the endocannabinoid system has a documented role in uterine contractility and in the modulation of pelvic pain, making it a plausible biological target โ€” something very different from a simple wellness trend with no scientific basis.

2. The real mechanism of menstrual pain: prostaglandins ๐Ÿ”ฌ

Where the pain actually comes from

In primary dysmenorrhea, pain originates from the release of prostaglandins โ€” mainly prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2ฮฑ) โ€” at the start of menstruation. These substances trigger uncoordinated, non-rhythmic uterine contractions, which reduce blood flow to the uterus, create low tissue oxygen levels (hypoxia), and are directly responsible for the characteristic painful cramps.

This mechanism explains why nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis, are effective for many women: they attack the biochemical cause of the pain directly. It's also the necessary starting point for understanding why the endocannabinoid system, which interacts directly with this same inflammatory pathway, is a research target with genuine physiological rationale โ€” not a baseless notion.

3. The endocannabinoid system in the uterus ๐Ÿงฌ

Components present directly in uterine tissue

The endocannabinoid system (ECS) is made up of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), the CB1, CB2, GPR18, and GPR55 receptors, and the TRPV1 channel. Studies in animal models have found that CB1 receptors play a direct role in relaxing the myometrium (the uterus's muscular layer).

When the endocannabinoid system is activated in experimental models, uterine contractions decrease and the muscle becomes less active; conversely, blocking CB1 receptors makes the uterus contract more forcefully. This direct causal relationship โ€” CB1 activation = less contraction; CB1 blockade = more contraction โ€” is the central biological foundation behind scientific interest in cannabinoids as a potential tool for managing menstrual pain.

4. The connection between endocannabinoids and prostaglandins ๐Ÿ”—

Two systems that don't act in isolation

Research has found that 2-AG correlates positively with prostaglandin E2, suggesting a direct link between the endocannabinoid system and the inflammatory pain described in section 2. Tissue concentrations of anandamide and 2-AG vary depending on the phase of the cycle, and uteri in the diestrus phase show spontaneous phasic contractions mediated by prostaglandins that are reduced by CB1 agonists (and, to a lesser extent, by CB2 agonists).

This biochemical interaction between endocannabinoids and prostaglandins is precisely what makes it mechanistically plausible that compounds acting on the endocannabinoid system could influence the same inflammatory cascade that causes menstrual pain โ€” this isn't a relationship invented by marketing, but a real signaling pathway studied in uterine tissue.

5. How the endocannabinoid system changes throughout the cycle ๐Ÿ“…

Gene expression of the endocannabinoid system's components in the endometrium isn't constant: it varies across the different phases of the menstrual cycle, suggesting active hormonal regulation of this system in uterine tissue. This cyclical pattern reinforces the idea that the endocannabinoid system isn't a passive player in menstrual physiology, but an actively regulated component that could help explain, at least in part, why pain intensity and response to different treatments vary so much between women โ€” and between cycles in the same woman.

FAAH: the enzyme that breaks down anandamide

FAAH (fatty acid amide hydrolase) is the main enzyme responsible for breaking down anandamide, and it has been implicated in the survival of endometrial stromal cells in ectopic endometriosis lesions, which has made it a target of considerable interest as a possible pharmacological target for modulating pain at both peripheral and central levels.

6. The CBD suppository study: what it actually found ๐Ÿ“Š

The first study of its kind with a commercial product

A study published in npj Women's Health in August 2024 evaluated the on-demand use of a commercial, broad-spectrum, high-CBD (100 mg) hemp-derived vaginal suppository, compared against a usual-care group (CBD group: n=77; control group: n=230), with baseline assessments and two monthly follow-ups (approximately two menstrual cycles).

The group using the CBD suppository showed a significant reduction in the frequency and intensity of menstrual symptoms, in the impact of those symptoms on daily activity, and in the need for and number of pain relievers used, compared with the usual-care group. Correlation analyses indicated a possible dose-dependent response: the more the suppository was used, the greater the symptom reduction.

The perceived improvement figure

Most participants in the CBD group reported at least moderate symptom improvement: 72.9% at the first follow-up and 81.1% at the second. According to the authors themselves, this is the first study to evaluate a commercial high-CBD suppository specifically in relation to menstrual symptoms.

A methodological limitation worth keeping in mind

The study's own design โ€” survey-based, without blind random assignment to a true placebo group โ€” means that, despite being a genuine step forward from the prior absence of data, it still doesn't reach the level of evidence of a randomized, placebo-controlled clinical trial, the usual gold standard in pharmacological research. This is a nuance worth bearing in mind when assessing the strength of the finding, without it taking away from being the first study of its kind with a commercially available product.

7. Why the route of administration matters as much as the dose ๐Ÿ’Š

Vaginal/rectal vs. oral vs. inhaled: not the same thing

The choice of vaginal suppository in the study described above wasn't arbitrary: this route of administration allows more direct absorption into pelvic tissue, partly bypassing the first-pass hepatic metabolism that orally ingested CBD undergoes โ€” a process that significantly reduces the amount of active compound that ultimately reaches circulation. This could help explain, at least in part, why relatively moderate doses of CBD delivered this way showed measurable effects on menstrual pain.

Smoked or vaporized cannabis, by contrast, offers a fast systemic absorption route through the lungs, with a pharmacokinetic profile completely different from that of a more locally acting suppository. No route is automatically "better" in absolute terms: each has its own absorption profile, onset, and duration, and the scientific evidence available for each specific route is still limited and uneven.

8. CBD vs. THC: different mechanisms, not interchangeable ๐Ÿงช

๐ŸŒฟ

CBD

Non-psychoactive. Acts more indirectly on the endocannabinoid system, with muscle-relaxant and anti-inflammatory properties documented in various contexts, without the intoxicating effect associated with THC.

๐Ÿ”ฅ

THC

Acts directly as an agonist of CB1 receptors, the same target involved in myometrial relaxation described in section 3 โ€” with the characteristic psychoactive effect as a trade-off.

Why this distinction matters in practice

CBD products โ€” including topicals and edibles โ€” may help relax the muscles and ease pain without causing the psychoactive effects associated with THC, making them a more manageable option for daytime use or work contexts. THC, acting more directly on CB1, might have a more potent mechanistic effect on uterine contractility, but with psychoactivity as a factor to weigh depending on each person's context.

9. Primary dysmenorrhea vs. endometriosis: not the same thing ๐ŸŽ—๏ธ

Two different sources of pain

Primary dysmenorrhea is menstrual pain without an identifiable structural cause, attributed mainly to the prostaglandin mechanism described in section 2. Endometriosis, by contrast, is a chronic disease in which endometrium-like tissue grows outside the uterus, causing inflammation, chronic pelvic pain (not only during menstruation), and, in many cases, an additional inflammatory component related to the endocannabinoid breakdown described in section 5.

Most recent research on cannabis and menstrual pain has focused specifically on women with endometriosis, precisely because this is a group with chronic pain that is often poorly controlled with conventional treatments and has a clear motivation to seek additional self-management strategies โ€” which explains why much of the prevalence and perceived-efficacy data cited in this guide comes from studies focused on endometriosis rather than primary dysmenorrhea without associated pathology.

10. PMS and PMDD: does cannabis apply here too? ๐ŸŒ™

Two different presentations of "classic" menstrual pain

Premenstrual syndrome (PMS) and its more severe form, premenstrual dysphoric disorder (PMDD), occur in the phase before menstruation โ€” not during bleeding itself โ€” and combine physical symptoms (bloating, breast tenderness, headache) with pronounced mood symptoms (irritability, anxiety, low mood). Their pathophysiology is more closely tied to individual sensitivity to the cycle's hormonal fluctuations than to the prostaglandin mechanism described in section 2.

The endocannabinoid system is also involved in regulating mood and stress response through CB1 receptors present in the central nervous system, which has led to some preliminary interest in cannabis for the mood symptoms of PMS/PMDD โ€” but the specific evidence in this area is still considerably scarcer and more preliminary than what's available for the physical pain of dysmenorrhea or endometriosis, so conclusions here should be treated with even more caution.

11. Topical application on the abdomen: what the evidence says ๐Ÿงด

A popular format with more limited scientific backing

Topical CBD products applied directly to the lower abdomen are a popular format among users, partly due to their ease of use and lack of systemic effects. However, unlike the suppository evaluated in the study in section 6, the specific evidence on whether topical CBD penetrates through the skin to reach the underlying uterine tissue in sufficient quantity to modulate muscle contractility is still very limited.

This doesn't mean topicals can't offer relief โ€” a local muscle-relaxant effect, or even an expectation/placebo component, isn't clinically irrelevant for someone seeking symptomatic relief โ€” but it does mean the topical abdominal route doesn't currently have the same level of specific research backing as the vaginal route studied in 2024, and its exact mechanism of action for this particular use is less well characterized.

12. How many women already use cannabis for this ๐Ÿ“ˆ

Widespread use that remains largely invisible

Across different studies, cannabis use prevalence among women with endometriosis ranges between 13% and 27%. A pooled analysis of nine cross-sectional studies, with a total of 1,787 participants, and a specific cross-sectional survey conducted in German-speaking countries (Germany, Austria, and Switzerland) with more than 900 women with confirmed endometriosis diagnoses, consistently confirm this magnitude of use.

This figure matters beyond statistical curiosity: it shows that a significant percentage of women are already incorporating cannabis into their management of menstrual or pelvic pain, often on their own initiative and without formal clinical supervision โ€” which reinforces the need for scientific research and medical guidance to keep pace with real-world practice.

13. What consumption methods are actually used ๐ŸŒฌ๏ธ

Among women who report using cannabis for endometriosis-related symptoms, pain is the most common indication, mentioned by between 57.3% and 95.5% of users depending on the study, followed by sleep and gastrointestinal discomfort (between 15.2% and 78.5%). As for the method of use, smoking is the most frequent, followed by edibles and vaping โ€” with suppositories and topicals, despite being the format with the most recent and specific clinical evidence (section 6), still representing a minority of the actual use reported in surveys.

Why the method of use also matters for long-term health

If menstrual pain is a symptom that recurs month after month, the chosen consumption route has implications beyond momentary pain relief: repeated smoking involves combustion and exposure to byproducts that aren't present in formats like suppositories, temperature-controlled vaping, or edibles. Anyone considering recurring cannabis use for menstrual pain may benefit from also reading our guide on vaping vs. smoking cannabis and its impact on lung health, since choosing a method isn't just a matter of personal preference, but of long-term cumulative exposure.

14. Perceived efficacy vs. quality of the evidence ๐Ÿ“‰

A contrast worth keeping in mind

Between 61% and 95.5% of women who use cannabis for endometriosis symptoms report pain relief, according to the various available surveys. That's a notably high range of perceived efficacy โ€” but it consists, overwhelmingly, of retrospective self-reported data, not controlled clinical trials with a placebo arm.

This distinction is crucial: perceived efficacy in surveys can be influenced by the placebo effect, recall bias, and the fact that those who continue using cannabis tend to be precisely the ones who perceive that it's working for them (survivorship bias in the sample). None of these factors invalidate the data, but they do require interpreting it with the same rigor as any other intermediate-level evidence, without over-interpreting it as equivalent to a randomized clinical trial.

15. The real limitations of current research โš ๏ธ

What still needs to be proven

There is a shortage of high-quality prospective longitudinal data and randomized controlled trials that rigorously evaluate the safety profile and efficacy of medicinal cannabis specifically for endometriosis-associated pain. The CBD suppository study itself, despite being the first of its kind with a commercial product, is a quasi-experimental, survey-based design, not a randomized, double-blind, placebo-controlled clinical trial.

This evidence gap doesn't mean the biological mechanisms described in sections 3 through 5 are false โ€” they're well documented in tissue and animal models โ€” but rather that translating those mechanisms into consistent, well-quantified clinical benefits in humans, with standardized doses and routes of administration, is still a work in progress.

16. Interactions and precautions to keep in mind โš ๏ธ

Cannabis isn't inert alongside other treatments
  • Anticoagulants and antiplatelet drugs โ€” CBD can interact with liver enzymes (CYP450) involved in the metabolism of several drugs, including some anticoagulants.
  • NSAIDs and standard pain relievers โ€” combining cannabis with your usual pain treatment isn't free of possible interactions; a prescribed treatment shouldn't be replaced without consulting a doctor first.
  • Hormonal contraceptives โ€” some cannabis components may interact with the hepatic metabolism of exogenous hormones, an area that still has limited research.
  • THC in work or driving contexts โ€” THC's psychoactive component can affect the ability to drive or perform tasks requiring full attention, a factor to weigh depending on the route and timing of use.

Before adding cannabis or CBD to menstrual pain management alongside any hormonal, anticoagulant, or chronic treatment already prescribed, the most responsible approach is to consult a healthcare professional, precisely because drug interactions remain an active area of research that isn't fully mapped out yet.

Dose and product quality matter too

Beyond drug interactions, the variability in dose and purity across CBD and cannabis products on the market โ€” especially outside channels with verified quality control โ€” adds an extra layer of uncertainty to any self-management of menstrual pain with these products. Choosing products with verifiable lab testing, and starting with low doses to observe individual response, are reasonable practical precautions while formal clinical research continues to advance.

CBD, medicinal cannabis, and their legal differences

In Spain, hemp-derived CBD products with THC content within legal limits can be marketed outside the strictly regulated medicinal cannabis circuit, while cannabis with higher THC concentrations โ€” including its formal medicinal use โ€” follows a different, more restrictive regulatory framework, with significant variation between European countries.

This article doesn't replace legal or medical advice on which specific products are accessible, legal, or advisable in your particular situation and jurisdiction; the regulatory framework for medicinal cannabis in Europe continues to evolve and differs notably from country to country.

18. Signs that the pain isn't "normal" and you should see a doctor ๐Ÿšจ

  • Pain that prevents daily activities on a recurring basis, month after month.
  • Pelvic pain outside the menstrual period, not limited to bleeding days.
  • Very heavy bleeding or large clots along with the pain.
  • Pain during sex that persists.
  • Progressive worsening of pain across cycles, rather than remaining stable.
Why this matters

These patterns can be a sign of endometriosis or other underlying gynecological conditions that require specific diagnosis and management, beyond the symptomatic relief that cannabis or any other pain reliever might offer. Cannabis can be a symptomatic management tool, but it doesn't replace a proper gynecological diagnosis.

19. Myths vs. reality ๐Ÿšซ

Widespread ideas worth qualifying
  • "Intense menstrual pain is normal and you just have to endure it" โ€” the pain has identifiable physiological mechanisms (prostaglandins), and when it's disabling, it can be a sign of an underlying condition that deserves evaluation.
  • "It's scientifically proven that cannabis cures menstrual pain" โ€” there's a plausible biological mechanism and promising preliminary data, but high-quality randomized clinical trials are still needed to confirm it with the rigor standard in medicine.
  • "CBD and THC do the same thing for this purpose" โ€” they act through different mechanisms: THC is a direct CB1 agonist (with psychoactivity), while CBD acts more indirectly and without an intoxicating effect.
  • "Smoking cannabis is the best route for menstrual pain" โ€” it's the most commonly used route according to surveys, but the only controlled trial available so far used a vaginal suppository, with a different absorption route.

20. Comparison table of administration routes ๐Ÿ“‹

Route Onset of action Specific clinical evidence
Vaginal suppository (CBD) Local, more direct โœ“ Quasi-experimental study published (npj Women's Health, 2024)
Smoked / vaporized Fast, systemic โžœ Self-reported survey data, no specific controlled trials
Edibles / oral Slow, systemic (with first-pass hepatic metabolism) โžœ Self-reported survey data, no specific controlled trials
Topical (cream/balm) Local, action limited to the applied area โœ— Specific evidence for menstrual pain still very limited

21. Frequently asked questions โ“

Why does menstruation hurt at a biological level?
Because of the release of prostaglandins (PGE2 and PGF2ฮฑ) at the start of bleeding, which trigger uncoordinated uterine contractions, reduce blood flow to the uterus, and create tissue hypoxia, causing the characteristic cramps.
What role does the endocannabinoid system play in the uterus?
CB1 receptors are involved in relaxing the myometrium; their activation reduces uterine contractions in experimental models, while blocking them intensifies contractions.
Are endocannabinoids and prostaglandins related?
Yes, 2-AG correlates positively with prostaglandin E2, suggesting a direct connection between the endocannabinoid system and the inflammatory pathway responsible for menstrual pain.
What did the CBD suppository study find?
A significant reduction in the frequency and intensity of menstrual symptoms and in pain-reliever use, with 72.9% and 81.1% of participants reporting at least moderate improvement at the two follow-ups in the study.
Are CBD and THC the same for menstrual pain?
No. THC acts as a direct agonist of CB1 receptors (with a psychoactive effect), while CBD acts more indirectly on the endocannabinoid system, without causing intoxication.
How many women with endometriosis use cannabis for pain?
Between 13% and 27% according to different studies, with a survey in German-speaking countries that included more than 900 women with confirmed diagnoses.
What's the most common method of use among users?
Smoking is the most frequently reported method in surveys, followed by edibles and vaping; suppositories and topicals still represent a minority of actual use.
What percentage of women report relief with cannabis?
Between 61% and 95.5% according to different surveys, though this is retrospective self-reported data, not controlled clinical trials with a placebo group.
Why isn't perceived efficacy the same as solid clinical evidence?
Because survey data can be influenced by the placebo effect, recall bias, and selection bias (those who keep using it tend to be the ones who feel it works), unlike a randomized trial with a control group.
Are there randomized clinical trials on cannabis and menstrual pain?
There's still a notable shortage of high-quality randomized controlled trials; the CBD suppository study is quasi-experimental and survey-based, not a double-blind, placebo-controlled trial.
Are primary dysmenorrhea and endometriosis the same thing?
No. Primary dysmenorrhea is menstrual pain without an identifiable structural cause, while endometriosis is a chronic disease in which endometrium-like tissue grows outside the uterus, causing pelvic pain outside of menstruation as well.
Why was a vaginal suppository used in the CBD study?
Because this route allows more direct absorption into pelvic tissue, partly avoiding the first-pass hepatic metabolism that reduces the amount of active CBD when taken orally.
What is FAAH and why does it matter?
It's the main enzyme that breaks down anandamide; it has been implicated in the survival of cells in endometriosis lesions and is a pharmacological target of interest for modulating pain.
Is the endocannabinoid system the same throughout the menstrual cycle?
No, gene expression of its components in the endometrium varies depending on the cycle phase, suggesting active hormonal regulation of this system.
Can cannabis interact with anticoagulants?
Yes, CBD can interact with liver enzymes (CYP450) involved in the metabolism of several drugs, including some anticoagulants, so it's advisable to consult a healthcare professional.
Can cannabis interact with hormonal contraceptives?
This is still an area with limited research; some cannabis components might interact with the hepatic metabolism of exogenous hormones, so prior medical consultation is advisable.
Is CBD legal for menstrual pain in Spain?
Hemp-derived CBD products with THC within legal limits can be marketed outside the strictly regulated medicinal cannabis circuit, while the framework for higher-THC cannabis is different and more restrictive.
What symptoms indicate that menstrual pain isn't "normal"?
Pain that recurringly prevents daily activities, pelvic pain outside the period, very heavy bleeding, pain during sex, or progressive worsening month after month.
Does cannabis replace a gynecological diagnosis?
No. It can be a symptomatic management tool, but intense or atypical menstrual pain requires a gynecological evaluation to rule out endometriosis or other underlying conditions.
Why do NSAIDs work for menstrual pain?
Because they inhibit prostaglandin synthesis, directly attacking the biochemical mechanism that causes uncoordinated uterine contractions and pain.
Does smoked THC have the same effect as a CBD suppository?
Not necessarily. They have different pharmacokinetic profiles (fast systemic absorption through the lungs versus more local, direct absorption via the vaginal route) and act on the endocannabinoid system through different mechanisms.
What other symptoms, besides pain, drive cannabis use in endometriosis?
Sleep and gastrointestinal discomfort are the next most commonly reported indications after pain, according to the available surveys.
Are there differences between European countries in access to medicinal cannabis for this?
Yes, the regulatory framework for medicinal cannabis varies significantly between European countries and continues to evolve, so it's worth checking the specific regulations in each jurisdiction.
Can CBD reduce the need for conventional pain relievers?
The CBD suppository study found a reduction in the need for and number of pain relievers used in the group that used it, compared with the usual-care group, though more research is needed to confirm this finding robustly.
Is it safe to combine cannabis with regular hormonal treatment?
There's no guarantee of an absence of interactions; it's advisable to consult a healthcare professional before combining cannabis or CBD with any hormonal or chronic treatment already prescribed.
Can cannabis help with PMS or PMDD, beyond physical pain?
There's preliminary interest because the endocannabinoid system also regulates mood, but the specific evidence for the mood symptoms of PMS/PMDD is still scarcer than what's available for the physical pain of dysmenorrhea.
Do topical CBD products applied to the abdomen work?
It's a popular format, but the evidence on whether topical CBD penetrates in sufficient quantity to reach uterine tissue is still very limited, unlike the vaginal suppository evaluated in the 2024 study.
What's the difference between PMS and menstrual pain (dysmenorrhea)?
PMS occurs before menstruation and combines physical and mood symptoms linked to hormonal fluctuations, while dysmenorrhea is pain during bleeding, linked mainly to the prostaglandin mechanism.
Are there cannabinoid receptors in the central nervous system related to mood?
Yes, CB1 receptors in the central nervous system are involved in regulating mood and stress response, which supports the preliminary interest in cannabis for premenstrual mood symptoms.
Important notice

This article is for informational and harm-reduction purposes only, and summarizes scientific evidence available at the time of publication. It doesn't replace an individualized medical or gynecological evaluation. If you experience intense, atypical, or disabling menstrual pain, consult a healthcare professional.

Real information, no empty promises

At Beetle Print, we believe that understanding the real science behind cannabis is the foundation of conscious, informed use.

View the Beetle Print catalog

Sources consulted

  • npj Women's Health (Nature) โ€” "A survey-based, quasi-experimental study assessing a high-cannabidiol suppository for menstrual-related pain and discomfort" (2024).
  • PMC โ€” "Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?".
  • PMC โ€” "Association of endocannabinoids with pain in endometriosis".
  • PubMed โ€” "Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle".
  • Scientific Reports (Nature) โ€” "Gene expression of the endocannabinoid system in endometrium through menstrual cycle".
  • PubMed โ€” "Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey".
  • Australian and New Zealand Journal of Obstetrics and Gynaecology (Wiley) โ€” "A Scoping Systematic Review of Cannabis Use in Endometriosis".
  • PMC โ€” "Evaluating the Current Evidence for the Efficacy of Cannabis in Symptom Management of Endometriosis-Associated Pain".

This article is for informational purposes only and does not constitute individualized medical advice. Scientific research on cannabis and menstrual/gynecological health continues to evolve actively. Always consult a healthcare professional with any questions related to your reproductive health.

Voltar para o blogue